At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed Nov 2, 2026 at 07:00 ET
Krystal Biotech reported Q3 2026 VYJUVEK revenue of $127.3M, up 30% YoY and above the $126.5M consensus. GAAP diluted EPS of $2.05 beat the $1.92 consensus. The company also authorized a $400M share repurchase program and provided positive KB113 clinical data in Gorlin syndrome.
- Q3 2026 VYJUVEK net product revenue of $127.3M, up 30% YoY from $97.8M
- GAAP diluted EPS of $2.05, above consensus estimate of $1.92
- Gross margin of 94% for the quarter
- Board authorized share repurchase program of up to $400 million
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access